Work

Managing leprosy reactions with secukinumab: Insights from a case series

Year: 2025

Type: article

Abstract: BACKGROUND: Erythema nodosum leprosum (ENL) is an immunological inflammatory reaction requiring precise management. Recalcitrant cases, their refractoriness to conventional therapy, and the adverse effects of standard treatments underline the need to explore alternative therapeutic options. METHODS: We conducted a retrospective study of five patients treated with secukinumab between January 2023 and January 2025. RESULTS: Patients showed clinical improvement with a reduced ENL frequency, neuritis relief, and corticosteroid sparing. CONCLUSIONS: Secukinumab appears to be a promising corticosteroid-sparing option for ENL, with a favorable safety profile. Further studies are required to confirm the efficacy and long-term safety of this treatment regimen.

Source: Revista da Sociedade Brasileira de Medicina Tropical

DOI: 10.1590/0037-8682-0118-2025

Authors: Luciana Vilela Gomide, João Paulo Turri Brufatto, Thiago Jessé Kucarz, Paulo Eduardo Neves Ferreira Velho, Andréa Fernandes Eloy da Costa França

Institutions: Universidade Estadual de Campinas (UNICAMP), Universidade Federal de Goiás

Language: English

Topic: Leprosy Research and Treatment

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: diamond

OpenAlex ID: W4414694263

FWCI:

Cites: 11

Cited by:

Related to: